Technology thesis · Biotechnology & Health
low conviction growthDigital therapeutics
No US federal reimbursement code for prescription DTx yet (the Access to PDT Act was reintroduced in May 2025 but not passed); the standalone-prescription model still works only via European schemes. Survivors win through payer/employer channels.
Position maintained continuously · last reviewed Jun 24, 2026
The thesis
US DTx commercial pathway requires federal reimbursement framework that doesn't yet exist
The Access to PDT Act lapsed in 2024 and was reintroduced in May 2025 (H.R.3288) but has not passed. State Medicaid coverage in MA + CT + NY + CO is emerging but insufficient. Without a permanent federal CMS code, US DTx companies depend on employer-benefit and cash-pay channels with structural growth ceilings. Pear's 2023 bankruptcy remains the cautionary tale.
European national schemes sustain DTx commercially where the US does not
Around 55 DiGA-listed apps in Germany are reimbursable by statutory health insurance - the only mature DTx channel. France's PECAN fast-track (live since 2023, DiGA-modelled) has underdelivered: by early 2025 no DTx had secured reimbursement and HAS had issued four negative PECAN assessments. UK NHS deploys Big Health Sleepio + Daylight. The DACH channel functions; France is not yet a reliable route; the US has none.
State of the art (2026)
The category has bifurcated. Standalone prescription DTx remains commercially stranded in the US: Pear Therapeutics liquidated in 2023, Akili delisted in 2024, and no federal CMS reimbursement code exists after the DTx Reimbursement Act lapsed. Yet the survivors that route through employer and payer channels are thriving – Hinge Health raised roughly 437m dollars at its May 2025 IPO and turned a Q1 profit, and Omada Health listed alongside it, ending the digital-health IPO drought. Otsuka and Click Therapeutics launched Rejoyn, the first FDA-cleared prescription DTx for major depressive disorder, in US app stores in 2024 and in Great Britain in June 2025. Germany DiGA still anchors the only mature reimbursement channel. The winning model is payer-contracted chronic and musculoskeletal care, not the standalone prescription.
Big Pharma partnerships provide regulatory + clinical validation without commercial scale
Click Therapeutics partnerships with Otsuka + Boehringer Ingelheim + Sanofi. Cognoa adjacencies with companies. Big pharma DTx co-development validates clinical efficacy but pharma sales channels don't unlock new payer reimbursement. Useful but not transformative for category.
Everything below is live inside CanaryIQ
The full analysis behind the verdict — the structure is real; the content unlocks when you log in.
Signal stack
Evidence stacked leading → lagging
Technology-native KPIs
Metrics that predict trajectory, tracked over time
Landscape map
Who builds what — and who depends on whom
Catalyst calendar
Dated events that will move the position
Technology roadmap
Milestones on the path to maturity
Watchlists
Companies, people and papers — each with a remove-by condition
Decision frameworks
The same call, framed for your desk
Thesis changelog
When our view changed, and why
Change our mind
5 disconfirming conditions
The rest is inside
You've read the verdict. The file is much deeper.
The full signal stack, technology-native KPIs tracked over time, the landscape of who depends on whom, the dated catalyst calendar, decision frameworks for every desk, live watchlists and the changelog of every time our call on Digital therapeutics has changed — all live inside CanaryIQ.